- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01840683
HELP Therapy for Dry AMD (HELPuc)
November 22, 2016 updated by: B.Braun Avitum AG
An Open-label, Single Center Study to Evaluate the Efficacy and Safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a Treatment for Non-exudative (Dry) Age-related Macular Degeneration (AMD)
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related Macular Degeneration (AMD).
A total of 14 clinic visits are scheduled, one baseline visit, 8 visits for H.E.L.P. therapy treatments (to be performed over a period of 12 weeks for each patient) and 5 follow-up visits to be performed one week following the 4th H.E.L.P. therapy session and 12 weeks, 24 weeks, 36 weeks and 52 weeks after the final H.E.L.P. therapy session.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W 1W9
- Canadian Centre for Advanced Eye Therapeutics Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of non-exudative (dry) AMD
- Male or female, between 50 and 90 years
- Presence of soft, confluent drusen in study eye
- At least one large (>125 μm) drusen
- Visual acuity (VA) between 20/32 and 20/100 Early treatment Diabetic Retinopathy Study (ETDRS) vision
- Fibrinogen level >100mg/dL
- Willing to continue lipid-lowering medication throughout the treatment phase if such medication was taken already before the study
- Willing to continue regular supplemental intake of Age related Eye Disease Study (AREDS) vitamins or comparable supplements throughout the study course
- Written informed consent
Exclusion Criteria (related to the underlying disease):
- Any evidence of wet AMD in either eye
- History of treatment for wet AMD in either eye
- Geographic atrophy involving fovea in study eye
- Fellow eye <20/400 VA
- Presence of cataract requiring treatment during study
- Presence of glaucoma requiring new treatment during study
- Presence of diabetic or other vascular retinopathy
- Previous retinal laser or surgical therapy
- Epiretinal membrane in study eye
- Any other ocular condition requiring therapy during the study
Exclusion Criteria (General):
- Participation in another clinical trial within 30 days
- Concurrent participation in another clinical trial
- Pregnancy or lactation
- Inability to give or understand informed consent
- Inability to maintain treatment and follow-up schedule
- Hypersensitivity to fluorescein
- Test positive for infectious status from HIV-, HBV- and HCV- infection
Exclusion Criteria (H.E.L.P. Apheresis):
- Heparin intolerance
- Heparin induced thrombocytopenia (HIT) II
- Hemorrhagic diathesis
- Ulcers in the gastrointestinal area
- Hemorrhage
- Coagulation disorder and neoplasm
- Liver diseases
- Severe heart failure and valvular defect
- Condition following apoplexia
- Dementia
- During pregnancy and lactation
- C1 esterase inhibitor deficiency or hereditary complement component 3 (C3) deficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA) in patients with non-exudative (dry) AMD.
Time Frame: Change from Baseline in the best corrected visual acuity (BCVA) at Week 24 after completion of H.E.L.P. therapy
|
Change from Baseline in the best corrected visual acuity (BCVA) at Week 24 after completion of H.E.L.P. therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the effects of H.E.L.P. therapy on the change in drusen area as assessed by colour photography.
Time Frame: Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
To evaluate the effects of H.E.L.P. therapy in area of abnormal autofluorescence as assessed by Fundus Autofluorescence (FAF).
Time Frame: Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
To evaluate the effects of H.E.L.P. therapy on overall visual functioning as assessed by the Visual Functioning Questionnaire (VFQ)-25 test.
Time Frame: Change from Baselineto Weeks 24 and 52 after completion of H.E.L.P. therapy
|
Change from Baselineto Weeks 24 and 52 after completion of H.E.L.P. therapy
|
To evaluate the safety of H.E.L.P. therapy by assessing laboratory tests and vital signs.
Time Frame: Baseline and at all HELP therapy sessions being conducted after Baseline within 12 weeks.
|
Baseline and at all HELP therapy sessions being conducted after Baseline within 12 weeks.
|
To evaluate the effects of H.E.L.P. on the integrity of the outer retinal bands as assessed by Optical Coherence Tomography (OCT)
Time Frame: Change from Baseline in integrity of the outer retinal bands at Weeks 24 and 52 after completion of H.E.L.P. therapy
|
Change from Baseline in integrity of the outer retinal bands at Weeks 24 and 52 after completion of H.E.L.P. therapy
|
To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA).
Time Frame: Change from Baseline to Week 52 after completion of H.E.L.P. therapy
|
Change from Baseline to Week 52 after completion of H.E.L.P. therapy
|
To evaluate the effects of H.E.L.P. therapy on the AREDS severity scale as assessed by colour photography.
Time Frame: Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
To evaluate the effects of H.E.L.P. therapy on the incidence and change in area of geographic hypo autofluorescence as assessed by fundus autofluorescence images.
Time Frame: Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
To evaluate the effects of H.E.L.P. on the drusen volume as assessed by Optical Coherence Tomography (OCT)
Time Frame: Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy
|
To evaluate the safety of H.E.L.P. therapy by assessing adverse events (AEs).
Time Frame: At all H.E.L.P. therapy sessions and follow-up visits being conducted after Baseline within 12 weeks and 12, 24, 36 and 52 weeks after completion of the H.E.L.P. therapy.
|
At all H.E.L.P. therapy sessions and follow-up visits being conducted after Baseline within 12 weeks and 12, 24, 36 and 52 weeks after completion of the H.E.L.P. therapy.
|
To evaluate the safety of H.E.L.P. therapy by physical examination.
Time Frame: At all H.E.L.P. therapy sessions being conducted after Baseline within 12 weeks and 52 weeks after completion of the H.E.L.P. therapy.
|
At all H.E.L.P. therapy sessions being conducted after Baseline within 12 weeks and 52 weeks after completion of the H.E.L.P. therapy.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fareed Ali, MD, FRCS(C), Canadian Centre for Advanced Eye Therapeutics Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2013
Primary Completion (Actual)
September 1, 2016
Study Completion (Actual)
November 1, 2016
Study Registration Dates
First Submitted
April 5, 2013
First Submitted That Met QC Criteria
April 23, 2013
First Posted (Estimate)
April 26, 2013
Study Record Updates
Last Update Posted (Estimate)
November 23, 2016
Last Update Submitted That Met QC Criteria
November 22, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BA-I-H-1202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-exudative (Dry) Age-related Macular Degeneration (AMD)
-
TyrogenexInternational Drug Development Institute; SynteractHCRTerminatedEye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Age-Related Macular Degeneration (AMD) | Exudative Age-related Macular Degeneration | AMD | Macular Degeneration, Age-related, 10United States
-
Oregon Health and Science UniversityCompletedNon-exudative Age-related Macular DegenerationUnited States
-
MacuCLEAR, Inc.UnknownNon-Exudative Age Related Macular DegenerationUnited States
-
Allegro Ophthalmics, LLCCompletedDry Age-related Macular DegenerationUnited States
-
Evergreen Therapeutics, Inc.Not yet recruitingNon-Exudative (Dry) Age-related Macular Degeneration (dAMD)
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
-
Subhransu K. Ray, M.D., Ph.D.Bay Area Retina AssociatesCompletedExudative Age-Related Macular DegenerationUnited States
-
Fondazione G.B. Bietti, IRCCSCompleted
-
Novartis PharmaceuticalsCompletedExudative Macular Degeneration | Neovascular Age-elated Macular Degeneration (Wet AMD)United States
-
Wake Forest University Health SciencesModulightWithdrawnExudative Age Related Macular DegenerationUnited States
Clinical Trials on H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
-
Universita di VeronaCompletedDiabetes Mellitus | Foot Ulcers | Arteriosclerosis ObliteransItaly